BPC-157: what the FDA actually said, and what the trials show
Our September 2026 PubMed search returned no records tagged as clinical trials for BPC-157, against 344 for semaglutide. That filter misses small uncontrolled human studies, including a two-person intravenous safety pilot published in 2025. The FDA, meanwhile, has looked at BPC-157 twice and both times ended up in the same place: it doesn't have enough safety information to say whether the peptide would hurt someone.
What this comes down to
- The September 2026 search returned no trial-tagged BPC-157 records. Small human pilot studies exist; that search result does not cover all human research.
- The FDA placed BPC-157 in category 2 of its compounding interim policy — the category for substances with identified significant safety risks — and the nomination was later withdrawn by whoever filed it.
- BPC-157 is not the active ingredient of any product in Drugs@FDA, and it is not on the 503A bulks list, so a pharmacy compounding it is outside the three routes the FDA names.
- Human reports include a knee-pain chart review, a bladder-pain pilot and a two-person intravenous safety pilot. These small uncontrolled studies cannot establish broad safety or efficacy.
- Semaglutide344
- BPC-1570
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered whether BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and Semax should be added to the 503A bulks list, the list that lets a state-licensed pharmacy compound a substance with no approved product. The FDA's own briefing document proposed that none of the seven be added[3]. Trade press reports that the committee disagreed for six of them: 8 to 6 with one abstention for BPC-157, KPV and TB-500 together, 7 to 5 for MOTS-c, and yes votes for epitalon and Semax, with emideltide voted down[4]. The vote is advisory. As of October 2026 the FDA and HHS have not added any of them to the list, so the legal position of BPC-157 described here has not changed.
Small human studies can escape a trial filter
Much of the BPC-157 literature is preclinical. In our September 2026 search, the publication-type filter returned no BPC-157 records, against 344 for semaglutide and 28 for tesamorelin. A positive comparison shows that a search can find tagged papers; it doesn't establish that every human study has that tag.
The search behind that claim. A PubMed search finds 0 results; the same search for semaglutide finds 344.
One human report is a retrospective chart review at a single hormone clinic in Orlando, covering 17 people who got BPC-157 injected into a knee, published in a complementary-medicine journal[5]. Sixteen were reached by phone afterward and asked to rate their pain from memory. That's a case series with a follow-up call attached — useful for deciding whether something is worth studying, not for deciding whether it works. A 2024 bladder-pain pilot and a 2025 intravenous safety pilot are additional human reports, both uncontrolled.[2][1]
What the FDA has on the record
A pharmacy compounding under section 503A can only use a bulk substance that meets one of three conditions: it complies with a USP or National Formulary monograph, or it's a component of an FDA-approved drug product, or it appears on the FDA's 503A bulks list[6]. BPC-157 isn't on the bulks list. It also isn't the active ingredient of anything in Drugs@FDA — we queried the database by ingredient, and a deliberately fake ingredient name returned the same empty result, so we ran tesamorelin through as a control and it came back with one approved product[8].
It went further than that. When the agency sorted the substances people had nominated for the bulks list, BPC-157 landed in category 2 — the bucket for substances where the FDA has identified significant safety risks and says plainly it does not intend to extend its hands-off policy. The nomination was later withdrawn by the party that filed it, which is why BPC-157 now sits in the withdrawn table rather than the live one[7]. Withdrawal isn't exoneration. The safety text the agency wrote is still published beside the name.
“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
[7]
The FDA didn't say BPC-157 is dangerous. It said it doesn't know, and that not knowing is itself the problem for an injectable a compounder would make in batches. Two separate concerns are stacked in there: whether the molecule does harm, and whether a given vial contains what the label says. Peptide impurities and characterization are the second question, and a page that only argues about the first one is answering half of it.
What that means for a company selling it to you
A telehealth company offering BPC-157 is offering a compounded preparation of a substance with no approved product behind it and only small uncontrolled human reports to point at. Some are upfront about that. Others describe it in the register normally reserved for medicine, which is where the FDA's authority over promotional claims comes in: prescription drug promotion by a compounder has to be truthful and non-misleading, and the agency says it monitors it[9].
Our own read of a seller is about the seller — what it publishes, what it withholds, and what it charges once the introductory rate ends. The method is on how we grade, and the price rules are on how we verify prices. Neither is a judgment about whether a molecule works, and this article isn't one either.
Where BPC-157 sits against the rest of the peptide menu
It is not the weakest thing on a typical peptide menu, and it is nowhere near the strongest. We put every peptide these companies sell through the same two questions — is there an approved product, and how many trial-tagged publications the search finds — in the peptide status table.
Questions people actually ask
Is BPC-157 legal to buy in the United States?
It isn't a scheduled drug, but it also isn't an approved one, and it isn't on the FDA's 503A bulks list — so a pharmacy compounding it is operating outside the three routes the agency names for bulk substances. Products sold as research chemicals and labeled not for human consumption are a separate problem: the FDA has warned companies for selling exactly that kind of listing directly to consumers with dosing instructions attached.
Has BPC-157 been tested in humans at all?
Yes. Published reports include a knee-pain chart review, a 12-patient bladder-pain pilot and a two-person intravenous safety pilot. They are small and uncontrolled, so they cannot establish general safety or efficacy.[1][2]
Why do so many telehealth companies sell it then?
Because compounding sits outside the approval process, and demand for it is real. A compounded preparation doesn't need a trial behind it to be dispensed on a prescription, which is the same mechanism that lets compounded GLP-1s exist. The difference is that semaglutide has hundreds of trials and an approved product; BPC-157 has no approved product and only limited human evidence.
Does the FDA say BPC-157 is unsafe?
No. It says it lacks enough safety information to know whether the peptide would cause harm in people, and that compounded versions carry risks around immunogenicity and impurities. Those are different statements, and the difference matters.
Sources
Every source below was read for this article, with the claim it supports written beside it.
- 1.Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 2025. PMID 40131143An uncontrolled intravenous safety pilot in two adults with short follow-up; it cannot establish general safety or a placebo-comparative adverse-event rate.
- 2.Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine, 2024. PMID 39325560An uncontrolled pilot in 12 women with interstitial cystitis; a human report outside the knee-pain chart review.
- 3.FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. U.S. Food and Drug Administration, 2026. Source · Document dated July 2026The committee was asked whether BPC-157, KPV, TB-500 and MOTS-c (July 23) and emideltide, epitalon and Semax (July 24) should be added to the 503A bulks list. For each one, in both the free-base and acetate forms, the FDA's own proposal was that it NOT be included. The document says the FDA will not issue a final determination until the committee's input has been considered.
- 4.FDA Panel Backs 6 Peptides for Compounding. AJMC (trade press report of the committee vote), 2026. SourceTrade press, not an FDA document: the committee voted 8-6 with 1 abstention to recommend BPC-157, KPV and TB-500, 7-5 with 2 abstentions for MOTS-c, also recommended epitalon and Semax, and voted emideltide down 7-6 with 1 abstention.
- 5.Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 2021. PMID 34324435 · Read September 2026This paper reports a retrospective chart review of 17 patients at one clinic, with 16 reached by telephone for follow-up.
- 6.Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration, 2026. Source · Read September 2026A 503A compounder may use a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list.
- 7.Substances in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026. Source · Document dated April 2026; read September 2026BPC-157 was placed in category 2 of the FDA's compounding interim policy and appears in the table of nominations later withdrawn by the nominators, with the agency's safety text published beside it.
- 8.Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. Source · Read September 2026No approved product in Drugs@FDA lists BPC-157 as an active ingredient; a control query for tesamorelin returned one approved product through the identical method.
- 9.Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, 2025. Source · Document dated September 2025; read September 2026Prescription drug promotion by or on behalf of compounders must be truthful, non-misleading and accurate, and the FDA says it monitors promotional material.
Key figures